Synovo Gmbh

Other

Merckle Gmbh

C-a-i-r Biosciences Gmbh

Jan-Hinrich Guse

Michael W Burnet

Hans-Jurgen Gutke

Mary Eggers

Gene Kim

Christiane Bauerlein

Michael Wolff

Irina Droste-Borel

Laurence Barker

Albert Beck

Ulrike Hahn

Georgia Tsotsou

Christiane Baeuerlein

Nikolas Pietrzik

Thomas Meindl

Simon Strass

Jeannette Reichert

Kattie Luyten

Maximilian Busch

Moussa Khobzaoui

Simona Margutti

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease.

Anti-infective and anti-inflammatory compounds

A method of treating cancer in which a compound that inhibits the expression, production or release of IL-10 by immune cells is combined with a compound that stimulates the production of IL-12 when given in combination with, or in the presence of TNFa. Said method is effective when provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of immune therapy including therapeutic vaccines.

Kinase modulators for the treatment of cancer

The invention provides novel compounds and compositions and methods for making and using the compounds and compositions. In particular, the use of organic acid salts promotes solubility. These more soluble forms are suitable for use in various diseases, notably diseases of lung, muscle, metabolism and eyesight.

Anti-inflammatory macrolides

The invention provides novel compounds and compositions and methods for making and using the compounds and compositions. 

The invention features novel macrocyclic compounds, methods of making the compounds, pharmaceutical compositions including the compounds, and methods of treatment using the compounds.

Macrocyclic compounds pounds and methods of use thereof

This invention features a method of identifying a compound useful for enhancing efficacy of a therapeutic agent. The method includes incubating a compound in blood cells; separating immune cells from erythrocytic cells; and determining the ratio of the concentration of the compound in the immune cells to the concentration of the compound in the erythrocytic cells; wherein the compound comprises a transportophore and a therapeutic agent, in which the transportophore is covalently bonded to the therapeutic agent via a bond or a linker.

Method of identifying improved conjugates of biologically active compounds

Macrocyclic compounds and methods of use thereof

This invention features a compound of the following formula:T-(-L-C), T is a transportophore, L is a bond or a linker having a molecular weight up to 240 dalton, C is a non-antibiotic therapeutic agent, and m is 1, 2, 3, 4, 5, 6, 7, or 8, in which the transportophore has an immune selectivity ratio of at least 2, the transportophore is covalently bonded to the non-antibiotic therapeutic agent via the bond or the linker, and the compound has an immune selectivity ratio of at least 2.

Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof

This invention features a compound of the following formula: wherein T is a transportophore, L is a bond or linker, and C is an antibiotic therapeutic agent, the transportophore is covalently bonded to the antibiotic therapeutic agent via the bond or the linker, and the transportophore is an azithromycin derivative or crown ether derivative.

Antibiotic conjugates

Growing community of inventors

Tubingen-Buhl, Germany

Jan-Hinrich Guse